Xbiotech Inc (XBIT) |
16.37 -0.25 (-1.5%)
|
01-20 23:54 |
Open: |
16.79 |
Pre. Close: |
16.62 |
High:
|
17.11 |
Low:
|
16.27 |
Volume:
|
63,124 |
Market Cap:
|
479M |
|
|
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. Its product candidates include 514G3, an anti-infective antibody that is in Phase II clinical trial for the treatment of Staphylococcus Aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development to treat Clostridium Difficile, influenza, Ebola, and Herpes Varicella Zoster (Chickenpox). XBiotech Inc. has a collaboration with BioBridge Global for the development of potential COVID 19 treatment based on natural antibodies from recovered patients. The company was founded in 2005 and is headquartered in Austin, Texas. |
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
17.15 - 17.234 |
17.234 - 17.303 |
Low:
|
16.042 - 16.154 |
16.154 - 16.245 |
Close:
|
16.214 - 16.383 |
16.383 - 16.519 |
|
Technical analysis |
as of: 2021-01-20 4:53:57 PM |
Overall:
|
|
Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
Target: |
Six months: 20.65 One year: 22.59 |
Support: |
Support1: 15.00 Support2: 12.48 |
Resistance: |
Resistance1: 17.68 Resistance2: 19.34 |
Pivot: |
16.51  |
Moving Average: |
MA(5): 16.62 MA(20): 16.55 
MA(100): 18.42 MA(250): 16.26  |
MACD: |
MACD(12,26): -0.32 Signal(9): -0.38  |
Stochastic oscillator: |
%K(14,3): 49.49 %D(3): 54.38  |
RSI: |
RSI(14): 42.79  |
52-week: |
High: 23.87 Low: 8.72 Change(%): -28.2 |
Average Vol(K): |
3-Month: 8946 10-Days: 8184 |
|
Price, moving averages and Bollinger Bands |
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.XBIT has closed above bottom band by 44.3%. Bollinger Bands are 13.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Headline News |
Tue, 19 Jan 2021 XBiotech Inc. (XBIT) Soars 1.59% on January 19 - Equities.com
Tue, 19 Jan 2021 XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy - GlobeNewswire
Mon, 11 Jan 2021 XBiotech Inc. (XBIT) Soars 1.54% on January 11 - Equities.com
Sat, 09 Jan 2021 XBiotech (NASDAQ:XBIT) Raised to "Hold" at BidaskClub - MarketBeat
Fri, 08 Jan 2021 XBiotech Inc. (XBIT) Soars 4.67% on January 08 - Equities.com
Mon, 04 Jan 2021 XBiotech Inc. (XBIT) Soars 3.32% on January 04 - Equities.com
|
Financial Analysis |
Growth |
 |
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
Profitability |
 |
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
Solvency |
 |
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
Efficiency |
 |
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. (M) |
29 |
Shares Float (M) |
18 |
% Held by Insiders
|
39.40 |
% Held by Institutions
|
14.40 |
Shares Short (K)
|
1,700 |
Shares Short P. Month (K)
|
1,690 |
Stock Financials |
EPS
|
16.450 |
EPS Est This Year
|
-1.290 |
EPS Est Next Year
|
-1.540 |
Book Value (p.s.)
|
11.840 |
Profit Margin
|
1748.38 |
Operating Margin
|
-68.85 |
Return on Assets (ttm)
|
-7.9 |
Return on Equity (ttm)
|
329.7 |
Qtrly Rev. Growth
|
|
Gross Profit (p.s.)
|
|
Sales Per Share
|
1.324 |
EBITDA (p.s.)
|
-0.836 |
Qtrly Earnings Growth
|
|
Operating Cash Flow (M)
|
-69 |
Levered Free Cash Flow (M)
|
-13 |
Stock Valuations |
PE Ratio
|
|
PEG Ratio
|
|
Price to Book value
|
1.38 |
Price to Sales
|
12.37 |
Price to Cash Flow
|
-6.99 |
Stock Dividends |
Dividend
|
|
Forward Dividend
|
|
Dividend Yield
|
|
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
7 Binary Options
|
Your Ad Here
|
|